Skip to main content

Table 1 Comparison of the baseline epidemiological characteristics of the different groups

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Characteristics Group P value
Total 1-CRZ 1-PP N1-PP
Total, n 73 32 28 13  
Gender, n (%)
 Male 36 (49.3) 19 (59.4) 11 (39.3) 6 (46.2) 0.290
 Female 37 (50.7) 13 (40.6) 17 (60.7) 7 (53.8)  
Median age, year (range) 51.4 (23–73) 53.3 (30–73) 49.6 (23–71) 43.2 (23–61) 0.045
Smoking, n (%)
Never 49 (67.1) 19(59.4) 21 (75.0) 9 (69.2) 0.431
Current/Former 24 (32.9) 13 (40.6) 7 (25.0) 4 (30.8)  
ECOG score, n (%)
0 or 1 69 (94.5) 30 (93.8) 26 (92.9) 13 (100.0) 0.625
> = 2 4 (5.5) 2 (6.2) 2 (7.1) 0 (0)  
Extent of disease, n (%)
Locally advanced 14 (19.2) 6 (18.8) 5 (17.9) 3 (23.1) 0.922
Metastatic 59 (80.8) 26 (81.2) 23 (82.1) 10 (76.9)  
  1. Note. — Unless otherwise indicated, the data are shown as numbers with percentages in parentheses. The statistical analysis for age was performed using the Mann–Whitney test. The statistical analyses for other clinical features were performed using the Chi-Square test